Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Xgeva | Denosumab (Drug Plan Submission) | Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer | List with clinical criteria and/or conditions | Complete | ||
Xiaflex | Collagenase clostridium histolyticum | Dupuytren’s contracture | List with criteria/condition | Complete | ||
XigDuo | dapagliflozin/metformin hydrochloride | Diabetes Mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Xofluza | baloxavir marboxil | Influenza | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | |||
Xolair | omalizumab | Chronic rhinosinusitis with nasal polyps | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Xolair | Omalizumab | Asthma, severe persistent | Cancelled | |||
Xolair | Omalizumab | Asthma, severe persistent | Do not list | Complete | ||
Xolair | Omalizumab | Chronic idiopathic urticaria | List with clinical criteria and/or conditions | Complete | ||
Xolair | Omalizumab (Drug Plan Submission) | Asthma, severe persistent | Reimburse with clinical criteria and/or conditions | Complete | ||
Xospata | Gilteritinib | Reimburse with clinical criteria and/or conditions | Complete | |||
Xpovio | selinexor | Multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Xtandi | Enzalutamide | Non-metastatic castration-resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Xtandi | Enzalutamide | mHSPC | Reimburse with clinical criteria and/or conditions | Complete | ||
Xtandi | Enzalutamide | First Line Metastatic Castration-Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Xtandi | Enzalutamide | Metastatic Castration Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Xultophy | insulin degludec + liraglutide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Xydalba | dalbavancin | Acute bacterial skin and skin structure infections | Reimburse with clinical criteria and/or conditions | Complete | ||
Xyrem | Sodium oxybate | Narcolepsy | Withdrawn | |||
Xyrem | Sodium oxybate | Narcolepsy | Do not list | Complete | ||
Yasmin | Drospirenone /ethinyl estradiol | Contraceptive, oral | List | Complete | ||
Yervoy | Ipilimumab | Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Yervoy | Ipilimumab | First Line Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Yescarta | axicabtagene ciloleucel | Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Yescarta | axicabtagene ciloleucel | Relapsed or refractory follicular lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Yondelis | Trabectedin | Metastatic Liposarcoma or Leiomyosarcoma | Do not reimburse | Complete |